Literature DB >> 16046394

Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis.

Yoonji Kim1, Kojiro Sato, Masataka Asagiri, Ikuo Morita, Kunimichi Soma, Hiroshi Takayanagi.   

Abstract

Bone homeostasis depends on the coordination of osteoclastic bone resorption and osteoblastic bone formation. Receptor activator of NF-kappaB ligand (RANKL) induces osteoclast differentiation through activating a transcriptional program mediated by the key transcription factor nuclear factor of activated T cells (NFAT) c1. Immunoreceptors, including osteoclast-associated receptor (OSCAR) and triggering receptor expressed by myeloid cells (TREM)-2, constitute the co-stimulatory signals required for RANKL-mediated activation of calcium signaling, which leads to the activation of NFATc1. However, it remains unknown whether the expression of immunoreceptors are under the control of NFATc1. Here we demonstrate that the expression of OSCAR, but not that of TREM-2, is up-regulated during osteoclastogenesis and markedly suppressed by the calcineurin inhibitor FK506, suggesting that OSCAR is transcriptionally regulated by NFATc1. NFATc1 expression results in the activation of the OSCAR promoter, which was found to be further enhanced by co-expression of PU.1 and microphthalmia-associated transcription factor (MITF). We further provide evidence that NFATc1 specifically regulates OSCAR by chromatin immunoprecipitation assay and quantification of OSCAR and TREM-2 mRNA in NFATc1-/- cells. Thus, OSCAR but not TREM-2 is involved in the positive feedback loop of the immunoreceptor-NFATc1 pathway during osteoclastogenesis. Although several immunoreceptors have been identified as co-stimulatory molecules for RANKL, the expression and function are differentially regulated. These mechanisms, possibly together with the delicate regulation of their ligands on osteoblasts, may provide the exquisite machinery for the modulation of osteoclastogenesis in the maintenance of bone homeostasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046394     DOI: 10.1074/jbc.M505820200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

Review 1.  The skeletal subsystem as an integrative physiology paradigm.

Authors:  Aaron J Weiss; Jameel Iqbal; Neeha Zaidi; Jeffrey I Mechanick
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

2.  Wogonin inhibits osteoclast differentiation by inhibiting NFATc1 translocation into the nucleus.

Authors:  Xiaolin Geng; Libin Yang; Chao Zhang; Hua Qin; Qiudong Liang
Journal:  Exp Ther Med       Date:  2015-07-03       Impact factor: 2.447

3.  Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation.

Authors:  Junwon Lee; Kabsun Kim; Jung Ha Kim; Hye Mi Jin; Han Kyung Choi; Seoung-Hoon Lee; Hyun Kook; Kyung Keun Kim; Yoshifumi Yokota; Soo Young Lee; Yongwon Choi; Nacksung Kim
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

Review 4.  Signaling networks that control the lineage commitment and differentiation of bone cells.

Authors:  Carrie S Soltanoff; Shuying Yang; Wei Chen; Yi-Ping Li
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

5.  Defective entry into mitosis 1 (Dim1) negatively regulates osteoclastogenesis by inhibiting the expression of nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1).

Authors:  Daniel An; Kyunghwan Kim; Wange Lu
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

6.  JMJD5, a Jumonji C (JmjC) domain-containing protein, negatively regulates osteoclastogenesis by facilitating NFATc1 protein degradation.

Authors:  Min-Young Youn; Atsushi Yokoyama; Sally Fujiyama-Nakamura; Fumiaki Ohtake; Ken-ichi Minehata; Hisataka Yasuda; Takeshi Suzuki; Shigeaki Kato; Yuuki Imai
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

7.  miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway.

Authors:  Chenyang Zhao; Weijia Sun; Pengfei Zhang; Shukuan Ling; Yuheng Li; Dingsheng Zhao; Jiang Peng; Aiyuan Wang; Qi Li; Jinping Song; Cheng Wang; Xiaolong Xu; Zi Xu; Guohui Zhong; Bingxing Han; Yan-Zhong Chang; Yingxian Li
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

8.  Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.

Authors:  Masashi Miyazaki; Yosuke Fujikawa; Chikahiro Takita; Hiroshi Tsumura
Journal:  Clin Rheumatol       Date:  2006-04-04       Impact factor: 2.980

9.  Mitf induction by RANKL is critical for osteoclastogenesis.

Authors:  Ssu-Yi Lu; Mengtao Li; Yi-Ling Lin
Journal:  Mol Biol Cell       Date:  2010-03-31       Impact factor: 4.138

10.  Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts.

Authors:  Yukiko Kuroda; Koichi Matsuo
Journal:  World J Orthop       Date:  2012-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.